Innate Pharma (NASDAQ:IPHA) Receives "Buy" Rating from HC Wainwright

Innate Pharma (NASDAQ:IPHA - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $11.50 price target on the stock.

Separately, Evercore ISI raised Innate Pharma to a "strong-buy" rating in a report on Monday, September 16th.

Innate Pharma Stock Up 2.7 %

Shares of IPHA traded up $0.05 during midday trading on Tuesday, hitting $1.90. 8,941 shares of the company traded hands, compared to its average volume of 9,060. The firm has a 50 day moving average of $2.07 and a 200-day moving average of $2.25. Innate Pharma has a 52 week low of $1.57 and a 52 week high of $3.15.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.